|
|
|
|
|
|
||
|
|
||||
|
|
||||
|
||||
Clinical Therapy Trials—Drug |
Departments of Neurosurgery (S.G., S.E., M.L.A., S.T.-U., J.H.S., A.H.F., H.S.F.), Medicine (I.C., J.N.R., J.A.Q.), Community and Family Medicine (J.E.H.), Neuro-radiology (J.M.P.), and Pathology (R.E.M.), Duke University Medical Center, Durham, NC 27710; Schering-Plough Corporation (V.S.-F., S.Z.), Kenilworth, NJ 07033; and Aventis (M.E.), Collegeville, PA 19426
1 Address correspondence and reprint requests to Sridharan Gururangan, Duke University Medical Center, DUMC Box 3624, Durham, NC 27710.
Abstract
Both GliadelTM wafers [1,3-bis(2-chloroethyl)-1-nitrosourea] and temozolomide (TEMO) have been shown in independent studies to prolong survival of patients with recurrent malignant glioma following surgery and radiotherapy. On the basis of preclinical evidence of synergism between Gliadel wafers and TEMO, a phase I study was designed to evaluate the toxicity of combining these 2 agents in the treatment of patients with recurrent supratentorial malignant glioma. All patients had surgical resection of the tumor at relapse, and up to 8 Gliadel (3.85%) wafers were placed in the surgical cavity following resection. Two weeks after surgery, TEMO was given orally daily for 5 days. Cohorts of 3 patients received TEMO at daily doses of 100 mg/m2, 150 mg/m2, and 200 mg/m2, respectively. Patients were assessed for toxicity 4 weeks after start of the first course of TEMO. Contrast-enhanced MRI of the brain was used to assess tumor response after the first cycle of TEMO. Patients with stable disease or response after the first cycle of TEMO were allowed to continue treatment at the same dose every 4 weeks for 12 cycles or until disease progression or unacceptable toxicity. Ten patients with a median age of 47 years (range, 22-66 years) were enrolled in this study. There were 7 patients with glioblastoma multiforme and 3 patients with anaplastic astrocytoma. Three patients were treated with TEMO at the first dose level of 100 mg/m2, 4 at the second dose level of 150 mg/m2, and 3 at the third dose level of 200 mg/m2. The 10 patients received a median of 3 cycles (range, 1-12 cycles) of TEMO following placement of Gliadel wafers. The treatment was well tolerated, with only 1 patient suffering grade III thrombocytopenia at the highest dose level. Two patients at each dose level had no evidence of disease progression after treatment. Four patients suffered progressive disease on therapy. Our study demonstrates that TEMO can be given safely after placement of Gliadel (3.85%) wafers. The recommended dosage for TEMO for a phase II study of this combination is 200 mg/m2 per day for 5 days.
References
Belanich, M., Pastor, M., Randall, T., and Guerra, D., Kibitel, J.,
Alas, L., Li, B., Citron, M., Wasserman, P., White, A., Eyre, H., Jaeckle, K.,
Schulman, S., Rector, D., Prados, M., Coons, S., Shapiro, W., and Yarosh, D.
(1996) Retrospective study of the correlation between the DNA
repair protein alkyltransferase and survival of brain tumor patients treated
with carmustine. Cancer Res.
56,783
-788.
Brem, H., Piantadosi, S., Burger, P.C., Walker, M., Selker, R., Vick, N.A., Black, K., Sisti, M., Brem, S., Mohr, G., Muller, P., Morawetz, R., and Schold, S.C., for the Polymer-Brain Tumor Treatment Group (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 345,1008 -1012.[CrossRef][Web of Science][Medline]
Chang, C.H., Horton, J., Schoenfeld, D., Salazer, O., Perez-Tamayo, R., Kramer, S., Weinstein, A., Nelson, J.S., and Tsukada, Y. (1983) Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group Study. Cancer 52,997 -1007.[CrossRef][Web of Science][Medline]
Dolan, M.E., and Pegg. A.E., (1997) O6-benzylguanine and its role in chemotherapy. Clin. Cancer Res. 3,837 -847.[Abstract]
Fine, H.A. (1994) The basis for current treatment recommendations for malignant gliomas. J. Neurooncol. 20,111 -120.[CrossRef][Medline]
Friedman, H.S., Dolan, M.E., Moschel, R.C., Pegg, A.E., Felker,
G.M., Rich, J., Bigner, D.D., and Schold, S.C., Jr. (1992)
Enhancement of nitrosourea activity in medulloblastoma and glioblastoma
multiforme. J. Natl. Cancer Inst.
84,1926
-1931.
Friedman, H.S., Johnson, S.P., Dong, Q., Schold, S.C., Rasheed,
B.K., Bigner, S.H., Ali-Osman, F., Dolan, E., Colvin, O.M., Houghton, P.,
Germain, G., Drummond, J.T., Keir, S., Marcelli, S., Bigner, D.D., and
Modrich, P. (1997) Methylator resistance mediated by mismatch
repair deficiency in a glioblastoma multiforme xenograft. Cancer
Res. 57,2933
-2936.
Friedman, H.S., McLendon, R.E., Kerby, T., Dugan, M., Bigner, S.H.,
Henry, A.J., Ashley, D.M., Krischer, J., Lovell, S., Rasheed, K., Marchev, F.,
Seman, A.J., Cokgor, I., Rich, J., Stewart, E., Colvin, O.M., Provenzale,
J.M., Bigner, D.D., Haglund, M.M., Friedman, A.H., and Modrich, P.L.
(1998) DNA mismatch repair and O6-alkylguanine-DNA
alkyltransferase analysis and response to Temodal in newly diagnosed malignant
glioma. J. Clin. Oncol.
16,3851
-3857.
Grossman, S.A., Reinhard, C., Colvin, O.M., Chasin, M., Brundrett, R., Tamargo, R.J., and Brem, H. (1992) The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers. J. Neurosurg. 76,640 -647.[Web of Science][Medline]
Hammond, L.A., Eckardt, J.R., Baker, S.D., Eckhardt, S.G., Dugan,
M., Forral, K., Reidenberg, P., Statkevich, P., Weiss, G.R., Rinaldi, D.A.,
Von Hoff, D.D., and Rowinsky, E.K. (1999) Phase I and
pharmacokinetic study of temozolomide on a daily-for-5 days schedule in
patients with advanced solid malignancies. J. Clin.
Oncol. 17,2604
-2613.
Horspool, K.R., Stevens, M.F., Newton, C.G., Lunt, E., Walsh, R.J., Pedgrift, B.L., Baig, G.U., Lavelle, F., and Fizames, C. (1990) Antitumor imidazotetrazines. 20. Preparation of the 8-acid derivative of mitozolomide and its utility in the preparation of active antitumor agents. J. Med. Chem. 33,1393 -1399.[CrossRef][Web of Science][Medline]
Hotta, T., Saito, Y., Fujita, H., Mikami, T., Kurisu, K., Kiya, K., Uozumi, T., Isowa, G., Ishizaki, K., and Ikenaga, M. (1994) O6-alkylguanine-DNA alkyltransferase activity of human malignant glioma and its clinical implications. J. Neurooncol. 21,135 -140.[CrossRef][Medline]
Jaeckle, K.A., Eyre, H.J., Townsend, J.J., Schulman, S., Knudson, H.M., Belanich, M., Yarosh, D.B., Bearman, S.I., Giroux, D.J., and Schold, S.C. (1998) Correlation of tumor O6-methylguanine-DNA methyl transferase levels with survival of malignant astrocytoma in patients treated with bis-chloroethylnitrosourea. A Southwest Oncology Group study. J. Clin. Oncol. 16,3310 -3315.[Abstract]
Lage, H., and Dietel, M. (1999) Involvement of the DNA mismatch repair system in antineoplastic drug resistance. J. Cancer Res. Clin. Oncol. 125,156 -165.[CrossRef][Web of Science][Medline]
Liu, L., Markowitz, S., and Gerson, S.L. (1996)
Mismatch repair mutations override alkyltransferase in conferring resistance
to temozolomide but not to 1,3-bis (2-chlorethyl) nitrosourea.
Cancer Res. 56,5375
-5379.
Ludlum, D.B. (1990) DNA alkylation by the haloethylnitrosoureas: Nature of modifications produced and their enzymatic repair or removal. Mutat. Res. 233,117 -126.[CrossRef][Web of Science][Medline]
Newlands, E.S., Blackledge, G.R., Slack, J.A., Rustin, G.J., Smith, D.B., Stuart, N.S., Quarterman, C.P., Hoffman, R., Stevens, M.F., and Brampton, M.H. (1992) Phase I trial of temozolomide (CCRG 81045: M&B 39831:NSC 362856). Br. J. Cancer 65,287 -291.[Web of Science][Medline]
Pegg, A.E. (1990) Mammalian
O6-alkylguanine-DNA alkyltransferase: Regulation and importance in
response to alkylating carcinogenic and therapeutic agents. Cancer
Res. 50,6119
-6129.
Plowman, J., Waud, W.R., Koutsoukos, A.D., Rubinstein, L.V., Moore,
T.D., and Grever, M.R. (1994) Preclinical antitumor activity of
temozolomide in mice: Efficacy against human brain tumor xenografts and
synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer
Res. 54,3793
-3799.
Schold, S.C., Jr., Kuhn, J.G., Chang, S.M., Bosik, M.E., Robins, H.I., Mehta, M.P., Spence, A.M., Fulton, D., Fink, K.L., and Prados, M.D. (2000) A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide. A North American Brain Tumor Consortium study. Neuro-Oncology [serial online], Doc. 99-26, December 9, 1999. URL http://neuro-oncology.mc.duke.edu. Neuro-Oncol. 2,34 -39.[Abstract]
Walker, M.D., Green, S.B., Byar, D.P., Alexander, E., Jr., Batzdorf, U., Brooks, W.H., Hunt, W.E., MacCarty, C.S., Mahaley, M.S., Jr., Mealey, J., Jr., Owens. G., Ransohoff, J., II, Robertson, J.T., Shapiro, W.R., Smith, K.R., Jr., Wilson, C.B., and Strike, T.A. (1980) Randomized comparisons of radiotherapy and nitrosoureas for treatment of malignant glioma after surgery. N. Engl. J. Med. 303,1323 -1329.[Abstract]
Wedge, S.R., Porteus, J.K., and Newlands, E.S. (1996) 3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity. Br. J. Cancer 74,1030 -1036.[Web of Science][Medline]
Yung, W.K.A., Prados, M.D., Yaya-Tur, R., Rosenfeld, S.S., Brada,
M., Friedman, H.S., Albright, R., Olson, J., Chang, S.M., O'Neill, A.M.,
Friedman, A.H., Bruner, J., Yue, N., Dugan, M., Zaknoen, S., and Levin, V.A.
(1999) Multicenter phase II trial of temozolomide in patients
with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse.
J. Clin. Oncol. 17,2762
-2771.
Yung, W.K.A., Albright, R.E., Olson, J., Fredericks, R., Fink, K., Prados, M.D., Brada. M., Spence, A., Hohl, R.J., Shapiro, W., Glantz, M., Greenberg, H., Selker, R.G., Vick, N.A., Rampling, R., Friedman, H., Phillips, P., Bruner, J., Yue, N., Osoba, D., Zaknoen, S., and Levin, V.A. (2000) A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br. J. Cancer 83,588 -593.[CrossRef][Web of Science][Medline]
CiteULike 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  D. A. Reardon, J. N. Rich, H. S. Friedman, and D. D. Bigner Recent Advances in the Treatment of Malignant Astrocytoma J. Clin. Oncol., March 10, 2006; 24(8): 1253 - 1265. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
